Follow the Third Harmonic Bio, Inc. share price and the full directors' dealings record of the company, a listed equity based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was filed on 14 August 2025 (J). Among the most active insiders: Conner Edward R.. Every trade is free.
23
Insider Decl.
n/a
Thresholds
€451,460
1 ops.
Buy Volume
€7m
1 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Third Harmonic Bio, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
28Σ signal
Buys €451,460€7m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Third Harmonic Bio, Inc. is a biopharmaceutical company focused on developing innovative therapies for immunological diseases. It is listed on NASDAQ under the ticker THRD.